Harpreet S. Dhaliwal, an officer of Vaxcyte, Inc., filed a Form 144 notice on November 12, 2026, proposing the sale of 17,000 shares of Vaxcyte common stock on NASDAQ.
Key Highlights
- Proposed sale: 17,000 shares of Vaxcyte, Inc. common stock with an aggregate market value of $1,153,101.50.
- Acquisition method: The 17,000 shares were acquired on November 11, 2026, through the exercise of stock options from the issuer, with cash payment on the same date.
- Shares outstanding: According to the filing, 158,299,981 shares of common stock were outstanding at the time of notice.
- Approximate sale date: November 11, 2026, through UBS Financial Services, Inc., acting as broker.
- Prior sales: Dhaliwal sold 17,000 shares on August 5, 2026, with gross proceeds of $935,066.15, in the three months preceding this notice.
- Rule 10b5-1 plan: The filing indicates a plan adoption or instruction date of April 6, 2026, with the sale relying on Rule 10b5-1.
Dhaliwal's Proposed Stock Sale Under Rule 144 at Vaxcyte
Harpreet S. Dhaliwal, identified as an officer of Vaxcyte, Inc. (NASDAQ:PCVX), filed a Form 144 notice of proposed sale with the U.S. Securities and Exchange Commission on November 12, 2026. According to the filing, Dhaliwal proposes to sell 17,000 shares of Vaxcyte common stock through UBS Financial Services, Inc., located at 11 Madison Ave, 4th Floor, New York, NY 10010, with an approximate sale date of November 11, 2026.
The filing states that the 17,000 shares were acquired on November 11, 2026, via the exercise of stock options granted by the issuer, with payment made in cash on the same date. The aggregate market value of the proposed sale is listed as $1,153,101.50, based on 158,299,981 total shares of common stock outstanding, according to the filing. The notice was signed by UBS Financial Services, Inc. as attorney-in-fact for Harpreet Dhaliwal.
The filing also discloses that within the three months prior to this notice, Dhaliwal sold 17,000 shares of Vaxcyte common stock on August 5, 2026, generating gross proceeds of $935,066.15. The filing indicates that the proposed sale is made in reliance on a Rule 10b5-1 trading plan or instruction adopted or given on April 6, 2026. Vaxcyte, Inc. is headquartered at 825 Industrial Road, Suite 300, San Carlos, California 94070.
What Was Disclosed
Vaxcyte officer Harpreet S. Dhaliwal filed a Form 144 on November 12, 2026, disclosing a proposed sale of 17,000 shares of common stock acquired through stock option exercise, with an aggregate market value of $1,153,101.50, in reliance on a Rule 10b5-1 plan adopted April 6, 2026.




Please wait processing your request...